HWAIL PHARM. CO., LTD Q3 revenue KRW 24.0 billion, operating loss of KRW 0.8 billion after profit a year earlier
AI summary · Not investment advice
Hwail Pharmaceuticals sold KRW 24.0 billion in the third quarter and lost KRW 0.8 billion from its main business, down from a profit a year earlier.
Operating profit · 3 months
KRW -780.7 million
Key facts
- Revenue (3 months)
- KRW 24.0 billion
- Net income (3 months)
- KRW -1.9 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 24.3 billion
- Revenue (year to date)
- KRW 71.9 billion
- Operating profit (prior-year 3 months)
- KRW 165.2 million
- Operating profit (year to date)
- KRW -2.3 billion
- Net income (prior-year 3 months)
- KRW 388.4 million
- Net income (year to date)
- KRW 3.0 billion
Commentary
AI commentary · Not investment advice
What happened
Hwail Pharm reported its consolidated results for the third quarter of 2026. Sales for the latest 3 months were KRW 24.0 billion. That is 1.3% lower than the same period a year earlier and 1.9% lower than the previous quarter.
In the company's terms
Operating profit (profit from the core business) for the 3 months was a loss of KRW 0.78 billion, a swing from a profit of KRW 0.17 billion a year earlier. Net income (final profit after taxes and all other items) for the 3 months was a loss of KRW 1.93 billion, a swing from a profit of KRW 0.39 billion a year earlier.
What changes for shareholders
For January 1 to September 30, cumulative sales were KRW 71.9 billion. Cumulative operating profit was a loss of KRW 2.26 billion. Cumulative net income was a profit of KRW 3.02 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
H